Akagi et al. (2015) incorporated the PDGF-receptor tyrosine kinase inhibitor imatinib in PLGA NPs and examined their efficacy in an MCT-induced model of PAH. Imatinib is used for the treatment of chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), and has resulted in 10-year progression-free survivals of 82% in CML (Kalmanti et al., 2015). It is important to note that a limitation of imatinib is patient resistance due to BCR-ABL1 amplification and multidrug-resistant P-glycoprotein (MDR-1) overexpression (Milojkovic and Apperley, 2009). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.